Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report)'s stock price dropped 8.7% during trading on Friday . The stock traded as low as $0.31 and last traded at $0.34. Approximately 46,071,262 shares traded hands during mid-day trading, an increase of 52% from the average daily volume of 30,282,193 shares. The stock had previously closed at $0.37.
Wall Street Analyst Weigh In
Separately, StockNews.com initiated coverage on shares of Tonix Pharmaceuticals in a research note on Monday. They set a "hold" rating on the stock.
View Our Latest Stock Analysis on TNXP
Tonix Pharmaceuticals Stock Performance
The firm's 50 day moving average price is $0.22 and its 200-day moving average price is $0.41. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The firm has a market capitalization of $63.10 million, a PE ratio of -0.01 and a beta of 2.23.
Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The business had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. On average, research analysts expect that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current year.
Tonix Pharmaceuticals Company Profile
(
Get Free Report)
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Featured Stories
Before you consider Tonix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tonix Pharmaceuticals wasn't on the list.
While Tonix Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.